AC Immune S.A. is a biotechnology company focused on developing therapies and diagnostics for neurodegenerative diseases, particularly Alzheimer's disease and other proteinopathies
The company utilizes its innovative approach to identify and target misfolded proteins that are implicated in these conditions. By leveraging advanced technology platforms, AC Immune is engaged in the discovery and development of disease-modifying treatments and biomarkers, aiming to address significant unmet medical needs in the field of neurology and enhance the understanding of these complex diseases.
Commodity prices regularly swing 25-30% or more in any given year. When this happens, the financial health of these firms can get dicey very quickly, given the amount of capital investment it requires to run them.
Unlocking hope for Alzheimer's with ACI-24.060. Takeda's agreement with AC Immune targets toxic forms of Abeta, potentially slowing disease progression.
